AstraZeneca Shares Sink on Lackluster Mystic Drug Results
AstraZeneca shares are tanking.
AstraZeneca (AZN) - Get Astrazeneca PLC Sponsored ADR Report posted lackluster trial results for a pipeline lung cancer drug - Mystic.
The drug didn't prove more effective than standard chemotherapy.
This was the very drug that helped AstraZeneca defend itself against Pfizer's $91 billion bid for the company three years ago.
Scroll to Continue
TheStreet Recommends
AstraZeneca shares are down over 15%.
